` ACAD (ACADIA Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

ACAD
vs
S&P 500

Over the past 12 months, ACAD has significantly outperformed S&P 500, delivering a return of 56% compared to the S&P 500's 9% growth.

Stocks Performance
ACAD vs S&P 500

Loading
ACAD
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ACAD vs S&P 500

Performance Gap Between ACAD and GSPC
HIDDEN
Show

Performance By Year
ACAD vs S&P 500

Loading
ACAD
S&P 500
Add Stock

Competitors Performance
ACADIA Pharmaceuticals Inc vs Peers

S&P 500
ACAD
ABBV
AMGN
GILD
VRTX
Add Stock

ACADIA Pharmaceuticals Inc
Glance View

Market Cap
3.8B USD
Industry
Biotechnology

ACADIA Pharmaceuticals Inc., nestled in the heart of biopharmaceutical innovation, has carved a niche as a trailblazer in tackling neurological and central nervous system disorders. The company's journey pivotally surrounds its flagship product, NUPLAZID (pimavanserin), which was approved by the FDA in 2016. Designed to address the psychosis associated with Parkinson’s disease, NUPLAZID opened new therapeutic doors, addressing a critical unmet medical need and improving patients’ quality of life. Leveraging this milestone, ACADIA has strategically focused on developing innovative therapies, extending its research into potential treatments for schizophrenia, major depressive disorders, and other neuropsychiatric conditions, thus widening its revenue streams and research portfolios. The company's financial engine is fueled primarily by sales of NUPLAZID, which has stood as a steady pillar in generating revenues. To amplify its growth trajectory, ACADIA emphasizes expanding NUPLAZID's usability through rigorous clinical trials aimed at securing approvals for additional indications. Concurrently, the company actively explores partnerships and acquisitions to broaden its pipeline, inaugurating an aspirational pursuit to revolutionize mental health treatment. With a keen eye on demographic trends and the increasing prevalence of CNS disorders globally, ACADIA Pharmaceuticals aligns its business operations not just on curing ailments, but on redefining health paradigms, thus reinforcing its sustainability in the competitive biopharmaceutical landscape.

ACAD Intrinsic Value
HIDDEN
Show
Back to Top